Monitoring cholinergic activity during attentional performance in mice heterozygous for the choline transporter: a model of cholinergic capacity limits. - Wikidata - wikimedia - TriplyDB

Monitoring cholinergic activity during attentional performance in mice heterozygous for the choline transporter: a model of cholinergic capacity limits.

Monitoring cholinergic activity during attentional performance in mice heterozygous for the choline transporter: a model of cholinergic capacity limits.

http://www.wikidata.org/entity/Q37397067

about

Cholinergic capacity mediates prefrontal engagement during challenges to attention: evidence from imaging genetics.Hemicholinium-3 sensitive choline transport in human T lymphocytes: Evidence for use as a proxy for brain choline transporter (CHT) capacity.Attention and the Cholinergic System: Relevance to Schizophrenia.Thalamic cholinergic innervation makes a specific bottom-up contribution to signal detection: Evidence from Parkinson's disease patients with defined cholinergic losses.Differential impact of genetically modulated choline transporter expression on the release of endogenous versus newly synthesized acetylcholine.The Neuroscience of Cognitive-Motivational Styles: Sign- and Goal-Trackers as Animal Models.

P2860

Q27307053-4CA3EC9A-E04D-4BC3-AE27-A86B7467A438 Q38430806-BBD9D50C-F61E-4CBA-9495-D8EA12D5E593 Q38897372-C1C93590-252D-42F3-8260-EA400F3414E3 Q39123187-677A05D3-E25E-4545-8215-348FD7133DBB Q41865432-7C9902CD-75B9-40A2-8266-ED746C43A96A Q48506194-64D81483-3E9A-4980-B8C7-6F93E4200B1C

P2860

Monitoring cholinergic activity during attentional performance in mice heterozygous for the choline transporter: a model of cholinergic capacity limits.

http://www.wikidata.org/entity/Q37397067

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Monitoring cholinergic activit ...... f cholinergic capacity limits.

@en

Monitoring cholinergic activit ...... f cholinergic capacity limits.

@nl

type

label

Monitoring cholinergic activit ...... f cholinergic capacity limits.

@en

Monitoring cholinergic activit ...... f cholinergic capacity limits.

@nl

prefLabel

Monitoring cholinergic activit ...... f cholinergic capacity limits.

@en

Monitoring cholinergic activit ...... f cholinergic capacity limits.

@nl

P1433

Q37397067-4D869991-319F-4E9C-9D77-37D63390C0A0

P1476

Q37397067-0377B7F8-832E-4773-8DBC-177A809CB063

P2093

Q37397067-0B059275-A258-4658-B132-FD4F27F2E6B2

Q37397067-95268F48-FA70-4B5D-A28B-6CF96D34711C

Q37397067-A1A16A69-CA76-400A-9414-76836131155A

Q37397067-D83F64BD-573C-4BC8-B3ED-77E669C90480

Q37397067-E4ACD5EE-B2ED-43A6-96AE-54194EB592EE

Q37397067-ED6CF26A-65D1-44F5-9CE4-97DE0EE06215

P2860

Q37397067-0481C4CA-E0CB-4179-B512-5BEAC915C35A

Q37397067-05E7E7D3-BEC0-4668-A358-08781C0F8643

Q37397067-08021BFE-971B-49D8-94A7-12478EDBEEE1

Q37397067-0874F762-FFB8-48B1-87A5-ADEE62AC0196

Q37397067-102B6442-89F2-4F68-95BF-FB9872B4608C

Q37397067-132D1402-C1FF-4028-8CB9-902861B99105

Q37397067-15FA37F2-7621-4D14-B157-851001B63965

Q37397067-1824DD18-3B8F-442E-92EE-F414809DD7F6

Q37397067-1910AC6B-7B14-4EC6-A2F2-9FF7513F9BAB

Q37397067-1987EB5C-7E84-40F1-86F7-B5C1CC993092

P304

Q37397067-85DA4BE2-5EEE-4BC8-89C1-4D6A6863627A

P31

Q37397067-28E07C0B-DD2C-493E-833D-36019B5FCBBA

P356

Q37397067-630846DC-6877-4B64-9F18-8BB5AE4244F8

P478

Q37397067-F59F20CA-46E3-4750-AA64-8C8A01DCC8AA

P577

Q37397067-D05854D2-DB4C-4862-AEF5-BBB3BC950AC3

P5875

Q37397067-DAB21EFA-0AB7-446A-9B99-E6989761BF09

P698

Q37397067-B07119B5-8CCD-44CB-ABF6-861B3368FBBE

P921

Q37397067-3207A5FF-E70E-40AF-9FB5-2322644BD914

P932

Q37397067-ED25213C-E04D-42C8-94B1-32A86999D00D

P356

J.NEUROPHARM.2013.07.032

P1433

Neuropharmacology

P1476

Monitoring cholinergic activit ...... f cholinergic capacity limits.

@en

P2093

Ajeesh Koshy Cherian

http://www.w3.org/2001/XMLSchema#string

Caitlin S Mallory

http://www.w3.org/2001/XMLSchema#string

Giovanna Paolone

http://www.w3.org/2001/XMLSchema#string

Martin Sarter

http://www.w3.org/2001/XMLSchema#string

Randy D Blakely

http://www.w3.org/2001/XMLSchema#string

Thomas R Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Single nucleotide polymorphism of the human high affinity choline transporter alters transport rate

Deficits in attentional control: cholinergic mechanisms and circuitry-based treatment approaches

Cognitive performance as a zeitgeber: cognitive oscillators and cholinergic modulation of the SCN entrain circadian rhythms

Par-4 inhibits choline uptake by interacting with CHT1 and reducing its incorporation on the plasma membrane

Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways

Lethal impairment of cholinergic neurotransmission in hemicholinium-3-sensitive choline transporter knockout mice

Muscarinic acetylcholine receptors in macaque V1 are most frequently expressed by parvalbumin-immunoreactive neurons

Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling

Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.

CNTRICS final biomarker selection: Control of attention.

P304

274-285

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEUROPHARM.2013.07.032

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255985334

http://www.w3.org/2001/XMLSchema#string

P698

23958450

http://www.w3.org/2001/XMLSchema#string

P921

P932

3865115

http://www.w3.org/2001/XMLSchema#string